Table A4.

Number, treatment duration, total payers’ cost, and total patients’ OOP cost per treatment regimen.

			Total cost (payers) [$]			Total OOP cost (patients) [$]
Treatment Regimen	Patients, n (%)	Mean treatment duration (months)	Mean	SD	Median	Mean	SD	Median	Patients with zero OOP cost, n (%)	Patients with OOP cost ≥10,000 (n)
Full Cohort
Dual therapy	1,514 (20.4)	6.3	21,372*	9,830	19,072	601†	1,396	304	154 (10.2%)	4
1DAA Triple	1,830 (24.7)	6.4	74,631*	21,904	77,603	811†	1,749	448	179 (9.8%)	12
2DAA Triple	181 (2.4)	3.1	101,715*	15,597	102,946	733†	1.782	292	28 (15.5%)	1
All-oral DAA	3,882 (52.4)	3.0	99,876*	47,006	92,836	933†	6,143	125	906 (23.3%)	59
HCV only
Dual therapy	1,469 (20.3)	6.3	21,262¶	9,761	19,041	607‡	1,416	302	149 (10.1%)	4
1DAA Triple	1,809 (25.1)	6.4	74,384¶	21,657	77,495	812‡	1,758	447	176 (9.7%)	12
2DAA Triple	174 (2.4)	3.1	101,508¶	15,661	103,016	750‡	1,815	292	27 (15.5%)	1
All-oral DAA	3,768 (52.2)	3.0	99,985¶	47,251	92,833	953‡	6,233	125	878 (23.3%)	59
HCV/HIV
Dual therapy	45 (24.1)	7.4	24,982¶	11,411	21,237	399‡	303	338	5 (11.1%)	0
1DAA Triple	21 (11.2)	7.8	95,877¶	31,590	97,191	672‡	603	473	3 (14.3%)	0
2DAA Triple	7 (3.7)	3.1	106,850¶	13,938	102,335	322‡	286	226	1 (14.3%)	0
All-oral DAA	114 (61.0)	2.9	96,303¶	38,022	92,886	264‡	659	108	28 (24.6%)	0

Abbreviations: 1DAA, First generation direct acting antivirals; 2DAA, Second generation direct acting antivirals; OOP, Out-of-pocket; SD, Standard deviation

^*Kruskal-Wallis test for difference in mean total cost (payers), Full Cohort: p<0.001

^†Kruskal-Wallis test for difference in mean OOP cost (patients), Full Cohort: p<0.001

^¶Kruskal-Wallis test for difference in mean total cost (payers), HCV only vs. HCV/HIV: p=0.094

^‡Kruskal-Wallis test for difference in mean OOP cost (patients), HCV only vs. HCV/HIV: p=0.023